A detailed history of Parametrica Management LTD transactions in Eli Lilly & CO stock. As of the latest transaction made, Parametrica Management LTD holds 1,800 shares of LLY stock, worth $1.4 Million. This represents 1.91% of its overall portfolio holdings.

Number of Shares
1,800
Previous 5,100 64.71%
Holding current value
$1.4 Million
Previous $4.62 Million 65.48%
% of portfolio
1.91%
Previous 6.11%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$772.14 - $960.02 $2.55 Million - $3.17 Million
-3,300 Reduced 64.71%
1,800 $1.59 Million
Q2 2024

Aug 07, 2024

BUY
$724.87 - $909.04 $3.7 Million - $4.64 Million
5,100 New
5,100 $4.62 Million
Q4 2023

Feb 02, 2024

SELL
$525.19 - $619.13 $2.53 Million - $2.98 Million
-4,809 Reduced 80.24%
1,184 $690,000
Q3 2023

Oct 31, 2023

SELL
$434.7 - $599.3 $774,635 - $1.07 Million
-1,782 Reduced 22.92%
5,993 $3.22 Million
Q2 2023

Aug 02, 2023

SELL
$350.74 - $468.98 $18,238 - $24,386
-52 Reduced 0.66%
7,775 $3.65 Million
Q1 2023

May 09, 2023

BUY
$310.63 - $364.82 $194,765 - $228,742
627 Added 8.71%
7,827 $2.69 Million
Q4 2022

Feb 07, 2023

BUY
$321.55 - $374.67 $734,098 - $855,371
2,283 Added 46.43%
7,200 $2.63 Million
Q3 2022

Nov 02, 2022

SELL
$296.48 - $337.87 $190,043 - $216,574
-641 Reduced 11.53%
4,917 $1.59 Million
Q2 2022

Jul 22, 2022

BUY
$278.73 - $327.27 $1.55 Million - $1.82 Million
5,558 New
5,558 $1.81 Million
Q4 2020

Feb 16, 2021

SELL
$130.46 - $172.63 $290,273 - $384,101
-2,225 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $325,339 - $376,314
2,225 New
2,225 $329,000
Q4 2018

Feb 12, 2019

SELL
$105.9 - $118.64 $261,361 - $292,803
-2,468 Closed
0 $0
Q3 2018

Nov 06, 2018

BUY
$85.86 - $107.31 $211,902 - $264,841
2,468 New
2,468 $265,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Parametrica Management LTD Portfolio

Follow Parametrica Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parametrica Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Parametrica Management LTD with notifications on news.